Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

674
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
674
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions01:27

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions

386
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
386
Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

610
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
610
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

704
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
704
Indirect-Acting Cholinergic Agonists: Pharmacokinetics01:22

Indirect-Acting Cholinergic Agonists: Pharmacokinetics

902
Indirect-acting cholinergic agonists, or anticholinesterases, enhance the body's cholinergic activity by inhibiting acetylcholine's breakdown. They are categorized as reversible or irreversible agents based on their mechanism of action. They are further classified into short-acting, intermediate-acting, and long-acting agents based on their duration of action.
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they...
902
Direct-Acting Cholinergic Agonists: Pharmacokinetics01:31

Direct-Acting Cholinergic Agonists: Pharmacokinetics

1.0K
Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
1.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hepatology nursing consultation in a tertiary hospital without liver transplantation: initial experience.

Revista espanola de enfermedades digestivas·2026
Same author

Impact of using waist-to-height ratio for diagnosing obesity in general digestive outpatient consultations.

Revista espanola de enfermedades digestivas·2026
Same author

Autoimmune hepatitis: what should be considered when conventional therapies fail?

Revista espanola de enfermedades digestivas·2025
Same author

Broadening perspectives in the treatment of chronic pouchitis.

Revista espanola de enfermedades digestivas·2024
Same author

Plummer-Vinson syndrome: is the immune system the missing piece?

Revista espanola de enfermedades digestivas·2024
Same author

Challenges in metastatic hepatocellular carcinoma: beyond tumor stage in guiding treatment.

Revista espanola de enfermedades digestivas·2024

Related Experiment Video

Updated: May 29, 2025

Subcutaneous Administration of Muscarinic Antagonists and Triple-Immunostaining of the Levator Auris Longus Muscle in Mice
07:09

Subcutaneous Administration of Muscarinic Antagonists and Triple-Immunostaining of the Levator Auris Longus Muscle in Mice

Published on: September 8, 2011

13.6K

11038 Neostigmine ̶̶ The underutilized drug worth remembering.

Carolina Broco Fernández1, Ana Belén Domínguez Carbajo1, Santiago Vivas Alegre2

  • 1Digestive Diseases, Complejo Asistencial Universitario de León, España.

Revista Espanola De Enfermedades Digestivas
|February 3, 2025
PubMed
Summary

Neostigmine effectively treats Ogilvie syndrome, a rare intestinal motility disorder, with a 70% success rate. This study suggests neostigmine is a safe and effective alternative to invasive treatments for this condition.

More Related Videos

Utilizing Transcranial Magnetic Stimulation to Study the Human Neuromuscular System
12:19

Utilizing Transcranial Magnetic Stimulation to Study the Human Neuromuscular System

Published on: January 20, 2012

26.6K
Author Spotlight: Translational Applications of Stimulated SFEMG in Rodent Models
04:30

Author Spotlight: Translational Applications of Stimulated SFEMG in Rodent Models

Published on: March 8, 2024

578

Related Experiment Videos

Last Updated: May 29, 2025

Subcutaneous Administration of Muscarinic Antagonists and Triple-Immunostaining of the Levator Auris Longus Muscle in Mice
07:09

Subcutaneous Administration of Muscarinic Antagonists and Triple-Immunostaining of the Levator Auris Longus Muscle in Mice

Published on: September 8, 2011

13.6K
Utilizing Transcranial Magnetic Stimulation to Study the Human Neuromuscular System
12:19

Utilizing Transcranial Magnetic Stimulation to Study the Human Neuromuscular System

Published on: January 20, 2012

26.6K
Author Spotlight: Translational Applications of Stimulated SFEMG in Rodent Models
04:30

Author Spotlight: Translational Applications of Stimulated SFEMG in Rodent Models

Published on: March 8, 2024

578

Area of Science:

  • Gastroenterology
  • Pharmacology

Background:

  • Ogilvie syndrome is a rare intestinal motility disorder.
  • It is associated with parasympathetic plexus dysfunction.
  • Complications include ischemia and perforation, particularly in comorbid patients.

Purpose of the Study:

  • To assess the efficacy and safety of neostigmine in treating Ogilvie syndrome.
  • To evaluate neostigmine as a potential first-line therapy.

Main Methods:

  • Retrospective observational study.
  • 13 patients with Ogilvie syndrome treated with neostigmine after failure of initial therapies.
  • Data collected from January 2021 to December 2023.

Main Results:

  • Symptom resolution in 70% of patients.
  • A single dose of neostigmine was successful in 54% of cases.
  • No severe adverse reactions were reported.

Conclusions:

  • Neostigmine demonstrates high efficacy and safety for Ogilvie syndrome.
  • It offers a viable therapeutic alternative to invasive interventions.